Treatment Options for Severe Acute Respiratory Syndrome, Middle East Respiratory Syndrome, and Coronavirus Disease 2019: a Review of Clinical Evidence

키워드

참고문헌 (100)

1. Sanders JM, "Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review", JAMA (2020)
2. Kim Sun Bean, "Interim Guidelines on Antiviral Therapy for COVID-19", Infection and Chemotherapy, 52(2), pp.281~304 (2020), 대한감염학회[DOI]
3. Hughes JP, "Principles of early drug discovery", Br J Pharmacol, 162, pp.1239~1249 (2011)
4. "COVID-19: reminder of the risks of chloroquine and hydroxychloroquine"[URL]
5. Lu R, "Genomic characterisation and epidemiology of 2019 novel coronavirus : implications for virus origins and receptor binding", Lancet, 395, pp.565~574 (2020)
6. Zhou P, "A pneumonia outbreak associated with a new coronavirus of probable bat origin", Nature, 579, pp.270~273 (2020)
7. Xiao K, "Isolation and characterization of 2019-nCoV-like coronavirus from Malayan Pangolins", bioRxiv 2020, ~ (2020)
8. Li W, "Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus", Nature, 426, pp.450~454 (2003)
9. Wrapp D, "Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation", Science, 367, pp.1260~1263 (2020)
10. World Health Organization (WHO), "Statement on the first meeting of the International Health Regulations (2005) emergency committee regarding the outbreak of novel coronavirus (2019-nCoV)", WHO, ~ (2020)
11. Tang X, "On the origin and continuing evolution of SARS-CoV-2", Natl Sci Rev, pp.nwaa036~ (2020)
12. Lessler J, "Incubation periods of acute respiratory viral infections : a systematic review", Lancet Infect Dis, 9, pp.291~300 (2009)
13. Park JE, "MERS transmission and risk factors : a systematic review", BMC Public Health, 18, pp.574~ (2018)
14. Guan WJ, "Clinical Characteristics of Coronavirus Disease 2019 in China", N Engl J Med, 382, pp.1708~1720 (2020)
15. Virlogeux V, "Association between severity of MERS-CoV infection and incubation period", Emerg Infect Dis, 22, pp.526~528 (2016)
16. Virlogeux V, "Brief report : Incubation period duration and severity of clinical disease following severe acute respiratory syndrome coronavirus infection", Epidemiology, 26, pp.666~669 (2015)
17. Jiang X, "Does SARS-CoV-2 has a longer incubation period than SARS and MERS?", J Med Virol, 92, pp.476~478 (2020)
18. "Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19)"[URL]
19. Epidemiology Working Group for NCIP Epidemic Response, "The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China", Zhonghua Liu Xing Bing Xue Za Zhi, 41, pp.145~151 (2020)
20. Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, 395, pp.497~506 (2020)
21. Guan WJ, "Clinical Characteristics of Coronavirus Disease 2019 in China", N Engl J Med, 382, pp.1708~1720 (2020)
22. Song P, "Cytokine storm induced by SARS-CoV-2", Clin Chim Acta, 509, pp.280~287 (2020)
23. Wu Z, "Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention", JAMA (2020)
24. World Health Organization (WHO), "WHO Director-General's opening remarks at the media briefing on COVID-19", ~ (2020)
25. Stockman LJ, "SARS : systematic review of treatment effects", PLoS Med, 3, pp.e343~ (2006)
26. Nyström K, "Ribavirin : pharmacology, multiple modes of action and possible future perspectives", Future Virol, 14, pp.153~160 (2019)
27. Sung JJ, "Severe acute respiratory syndrome : report of treatment and outcome after a major outbreak", Thorax, 59, pp.414~420 (2004)
28. Peiris JS, "Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia : a prospective study", Lancet, 361, pp.1767~1772 (2003)
29. Chan MH, "Serum LD1 isoenzyme and blood lymphocyte subsets as prognostic indicators for severe acute respiratory syndrome", J Intern Med, 255, pp.512~518 (2004)
30. Tsang K, "SARS: pharmacotherapy", Respirology, 8(Suppl), pp.S25~S30 (2003)
31. Dipiro JT, "Pharmacotherapy: a pathophysiologic approach" (2017), McGraw-Hill Education
32. Tsui PT, "Severe acute respiratory syndrome : clinical outcome and prognostic correlates", Emerg Infect Dis, 9, pp.1064~1069 (2003)
33. Tsang KW, "A cluster of cases of severe acute respiratory syndrome in Hong Kong", N Engl J Med, 348, pp.1977~1985 (2003)
34. Stern A, "Corticosteroids for pneumonia", Cochrane Database Syst Rev, 12, pp.CD007720.~ (2017)
35. Briel M, "Corticosteroids in patients hospitalized with community-acquired pneumonia : systematic review and individual patient data meta-analysis", Clin Infect Dis, 66, pp.346~354 (2018)
36. Leong HN, "Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003", Trop Med Int Health, 9, pp.923~927 (2004)
37. Vastag B, "Old drugs for a new bug : influenza, HIV drugs enlisted to fight SARS", JAMA, 290, pp.1695~1696 (2003)
38. Chan KS, "Treatment of severe acute respiratory syndrome with lopinavir", ritonavir : a multicentre retrospective matched cohort study, 2003, pp.9, 399~406
39. Chu CM, "Role of lopinavir", ritonavir in the treatment of SARS : initial virological and clinical findings, 2004, pp.59, 252~256
40. Fritsch SD, "Effects of interferons and viruses on metabolism", Front Immunol, 7, pp.630~ (2016)
41. Lin FC, "Interferons : success in anti-viral immunotherapy", Cytokine Growth Factor Rev, 25, pp.369~376 (2014)
42. Loutfy MR, "Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome : a preliminary study", JAMA, 290, pp.3222~3228 (2003)
43. Cheng Y, "Use of convalescent plasma therapy in SARS patients in Hong Kong", Eur J Clin Microbiol Infect Dis, 24, pp.44~46 (2005)
44. Soo YO, "Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients", Clin Microbiol Infect, 10, pp.676~678 (2004)
45. Chen CY, "Clinical features and outcomes of severe acute respiratory syndrome and predictive factors for acute respiratory distress syndrome", J Chin Med Assoc, 68, pp.4~10 (2005)
46. Ho JC, "Pentaglobin in steroid-resistant severe acute respiratory syndrome", Int J Tuberc Lung Dis, 8, pp.1173~1179 (2004)
47. Momattin H, "Therapeutic options for Middle East respiratory syndrome coronavirus(MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy", Int J Infect Dis, 17, pp.e792~e798 (2013)
48. 정용필, "Antiviral Treatment Guidelines for Middle East Respiratory Syndrome", Infection and Chemotherapy, 47(3), pp.212~222 (2015), 대한감염학회
49. Omrani AS, "Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection : a retrospective cohort study", Lancet Infect Dis, 14, pp.1090~1095 (2014)
50. Shalhoub S, "IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia : a retrospective study", J Antimicrob Chemother, 70, pp.2129~2132 (2015)
51. Jin Y, "Virology, epidemiology, pathogenesis, and control of COVID-19", Viruses, 12, pp.3722~ (2020)
52. Arabi YM, "Ribavirin and interferon therapy for critically ill patients with Middle East Respiratory Syndrome : a multicenter observational study", Clin Infect Dis, 70, pp.1837~1844 (2019)
53. McCreary EK, "Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options", Open Forum Infect Dis, 7, pp.ofaa105~ (2020)
54. Hung IF, "Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19 : an open-label, randomised, phase 2 trial", Lancet, 395, pp.1695~1704 (2020)
55. Cao B, "A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19", N Engl J Med, 382, pp.1787~1799 (2020)
56. Hu L, "Risk factors associated with clinical outcomes in 323 COVID-19 hospitalized patients in Wuhan, China", Clin Infect Dis, pp.ciaa539~ (2020)
57. Li Y, "An exploratory randomized controlled study on the efficacy and safety of lopinavir", ritonavir or arbidol treating adult patients hospitalized with mild, medRxiv, pp.2020, ~
58. Elfiky AA, "Anti-HCV, nucleotide inhibitors, repurposing against COVID-19", Life Sci, 248, pp.117477~ (2020)
59. Holshue ML, "First case of 2019 novel coronavirus in the United States", N Engl J Med, 382, pp.929~936 (2020)
60. The COVID-19 investigation team, "First 12 patients with coronavirus disease 2019 (COVID-19) in the United States", medRxiv, ~ (2020)
61. Wang Y, "Remdesivir in adults with severe COVID-19 : a randomised, double-blind, placebo-controlled, multicentre trial", Lancet, 395, pp.1569~1578 (2020)
62. "NIH clinical trial shows remdesivir accelerates recovery from advanced COVID-19"[URL]
63. Lim J, "The author's response : Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea : the application of lopinavir", ritonavir for the treatment of COVID-19 pneumonia Monitored by quantitative RT-PCR, 2020, pp.35, e79~
64. Han W, "The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019", J Med Virol, 92, pp.461~463 (2020)[DOI]
65. Young BE, "Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore", JAMA, 323, pp.1488~1494 (2020)
66. Baden LR, "Covid-19-The search for effective therapy", N Engl J Med, 382, pp.1851~1852 (2020)
67. Cai Q, "COVID-19 in a designated infectious diseases hospital outside Hubei Province, China", Allergy, 75, pp.1742~1752 (2020)
68. Yan D, "Factors associated with prolonged viral shedding and impact of lopinavir", ritonavir treatment in patients with SARS-CoV-2 infection, 2020, pp.56, 2000799~
69. "COVID-19 treatment guidelines: Lopinavir/ritonavir and other HIV protease inhibitors"[URL]
70. Wu J, "Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease(COVID-19)", J Intern Med, 288, pp.128~138 (2020)
71. Zhu Z, "Arbidol monotherapy is superior to lopinavir", ritonavir in treating COVID-19, 2020, pp.81, e21~e23
72. Deng L, "Arbidol combined with LPV", r versus LPV, J Infect, pp.2020, 81[DOI]
73. Cai Q, "Experimental treatment with favipiravir for COVID-19: an open-label control study", Engineering (Beijing) (2020)
74. Chen C, "Favipiravir versus arbidol for COVID-19: a randomized clinical trial", medRxiv, ~ (2020)
75. Shang L, "On the use of corticosteroids for 2019-nCoV pneumonia", Lancet, 395, pp.683~684 (2020)
76. Russell CD, "Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury", Lancet, 395, pp.473~475 (2020)
77. Alhazzani W, "Surviving sepsis campaign : guidelines on the management of critically ill adults with coronavirus disease 2019(COVID-19)", Intensive Care Med, 46, pp.854~887 (2020)
78. Rygård SL, "Low-dose corticosteroids for adult patients with septic shock : a systematic review with meta-analysis and trial sequential analysis", Intensive Care Med, 44, pp.1003~1016 (2018)
79. Arabi YM, "Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome", Am J Respir Crit Care Med, 197, pp.757~767 (2018)
80. Yao X, "In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)", Clin Infect Dis, 71, pp.732~739 (2020)
81. Cortegiani A, "A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19", J Crit Care, 57, pp.279~283 (2020)
82. Million M, "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin : A retrospective analysis of 1061 cases in Marseille, France", Travel Med Infect Dis, 35, pp.101738~ (2020)
83. Rosenberg ES, "Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State", JAMA, 323, pp.2493~2502 (2020)
84. Geleris J, "Observational study of hydroxychloroquine in hospitalized patients with Covid-19", N Engl J Med, 382, pp.2411~2418 (2020)
85. Mahévas M, "Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data", BMJ, 369, pp.m1844~ (2020)
86. Magagnoli J, "Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19", Med (N Y) (2020)
87. Yu B, "Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19", Sci China Life Sci, 15, pp.1~7 (2020)
88. Chen J, "A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19", Zhejiang Da Xue Xue Bao Yi Xue Ban, 49, pp.215~219 (2020)
89. Gautret P, "Hydroxychloroquine and azithromycin as a treatment of COVID-19 : results of an open-label non-randomized clinical trial", Int J Antimicrob Agents, 56, pp.105949~ (2020)
90. Sarma P, "Virological and clinical cure in Covid-19 patients treated with hydroxychloroquine : a systematic review and meta-analysis", J Med Virol, 92, pp.776~785 (2020)
91. Chen Z, "Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial", medRxiv, ~ (2020)
92. Bessière F, "Assessment of QT intervals in a case series of patients with coronavirus disease 2019(COVID-19)infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit", JAMA Cardiol, pp.e201787~ (2020)
93. Funck-Brentano C, "Chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous?", Lancet (2020)
94. Mair-Jenkins J, "The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology : a systematic review and exploratory meta-analysis", J Infect Dis, 211, pp.80~90 (2015)
95. Shen C, "Treatment of 5 critically ill patients with COVID-19 with convalescent plasma", JAMA, 323, pp.1582~1589 (2020)
96. Roback JD, "Convalescent plasma to treat COVID-19 : possibilities and challenges", JAMA, 323, pp.1561~1562 (2020)
97. 안진영, "Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea", Journal of Korean Medical Science, 35(14), pp.1~8 (2020), 대한의학회[DOI]
98. Liu T, "The potential role of IL-6 in monitoring severe case of coronavirus disease 2019", medRxiv, ~ (2020)
99. Xu X, "Effective treatment of severe COVID-19 patients with tocilizumab", Proc Natl Acad Sci U S A, 117, pp.10970~10975 (2020)
100. Jeong SJ, "Anti-vascular endothelial growth factor antibody attenuates inflammation and decreases mortality in an experimental model of severe sepsis", Crit Care, 17, pp.R97~ (2013)[DOI]

관련 논문AI추천